Dr. Lee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
- Brigham and Women's HospitalResidency, Internal Medicine, 2009 - 2012
- Duke University School of MedicineClass of 2009
Certifications & Licensure
- FL State Medical License 2021 - Present
- TX State Medical License 2020 - 2026
- AZ State Medical License 2023 - 2025
- TN State Medical License 2023 - 2025
- WA State Medical License 2023 - 2025
- GA State Medical License 2023 - 2024
- LA State Medical License 2023 - 2024
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC Start of enrollment: 2018 Mar 09
- Palbociclib and Cetuximab in Metastatic Colorectal Cancer Start of enrollment: 2018 Mar 13
- Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas Start of enrollment: 2019 Jan 24
Publications & Presentations
PubMed
- 2 citationsAddition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial.Ethan B Ludmir, Alexander D Sherry, Bryan M Fellman, Suyu Liu, Tharakeswara Bathala
Journal of Clinical Oncology. 2024-11-10 - 1 citationsMolecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival.Mahmoud Yousef, Abdelrahman Yousef, Saikat Chowdhury, Mohammad M Fanaeian, Mark Knafl
JAMA Oncology. 2024-11-01 - A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer.Hanna K Sanoff, Allison M Deal, Jai Patel, Jonathan D Sorah, Jacquelyne Gaddy
The Oncologist. 2024-09-06
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: